The device won the breakthrough nod for the treatment of episodic memory loss in adult patients with prior moderate-to-severe traumatic brain injury (TBI) and persistent memory deficits.

According to a news release, SNS becomes the first device to receive breakthrough designation for TBI-related memory loss. The company says no current FDA-cleared or approved therapies exist to treat memory loss.